

7 November 2019

## Despatch of Retail Offer Document

Phylogica Limited (**Company**) wishes to advise that it has today despatched the retail offer document relating to the fully underwritten accelerated non-renounceable entitlement offer announced on 31 October 2019 (**Entitlement Offer**).

### Commencement of the Retail Entitlement Offer

The retail component of the Entitlement Offer (**Retail Entitlement Offer**) will open today and will close at 5:00 pm (WST) on Monday, 18 November 2019 (unless varied).

Eligible shareholders on the record date of 5.00 pm (WST) on Monday, 4 November 2019, may participate in the Retail Entitlement Offer at the issue price of \$0.055 per new share, on the basis of 1 new share for every 5 shares held.

### Retail Investor Enquiries

If you have any queries concerning the Retail Entitlement Offer, or the action you are required to take to subscribe for new shares, please consult your stockbroker, accountant, solicitor or other professional advisor. For further information about the Retail Entitlement Offer you can call the Company on +61 8 6151 0992 at any time between 8:30am and 5:00pm (WST), Monday to Friday.

**ENDS** For further information, please contact:

#### INVESTORS

Rohan Hockings  
CEO  
info@pyctx.com

**NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES**

### About PYC Therapeutics

*Phylogica Limited trading as PYC Therapeutics (ASX: PYC) is a drug development company solving a major challenge in the development of a revolutionary new class of drugs – delivering large drugs into cells. Cell Penetrating Peptides (CPPs) can overcome ‘the delivery challenge’ and provide access for a wide range of potent and precise drug ‘cargoes’ to the ‘undruggable genome’ – the highest value drug targets that exist inside cells. PYC Therapeutics is using its CPP*

*platform to develop a pipeline of novel therapies with an initial focus on inherited retinal diseases.*

### **Forward looking statements**

Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and the Company's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. The Company undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.

This ASX announcement should not be relied on as a recommendation or forecast by the Company. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

---

Tel: +61 8 6151 0994

[pyctx.com](http://pyctx.com)

**Phylogica Limited trading as PYC Therapeutics**

ACN 098 391 961